Abstract: A carrageenan derivative according to the present disclosure can quickly and easily detect and label the presence of inflammation-related macrophages and, particularly, can accurately and easily identify M1-type macrophages highly associated with early inflammation. In addition, the carrageenan derivative has advantages in that it can be produced easily, environmental pollution is minimized because a small amount of organic solvent is used, and initial cost is low.

Abstract: The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer.

Abstract: A boron nitride composite is proposed. The boron nitride composite may include an aggregate including a plurality of boron nitride particles bonded to each other to form a plurality of pores. The boron nitride composite may also include a filler containing at least one of an organic material or an inorganic material, and filled in at least some of the plurality of pores such that the organic material and the inorganic material do not cover an outer surface of the aggregate.

Abstract: The present invention provides a high value-added method for resource recovery from lithium sludge and fluoride sludge, and an economic sludge treatment method, wherein lithium fluoride (LiF), which is an insoluble lithium compound, is prepared by reacting lithium sludge with fluoride sludge, and then Li—Al layered double hydroxide (LI-Al LDH), which is an insoluble lithium compound, is prepared by reacting reaction filtrate with an aluminum compound, after which a conversion product is prepared by a sulfation reaction of the Li—Al layered double hydroxide (LI-Al LDH), which is an insoluble lithium compound, with a sulfuric acid compound, a lithium concentrate is prepared by leaching the conversion product with water, and then the lithium concentrate is recirculated as a lithium raw material to efficiently and economically recover lithium ions contained in the lithium sludge, or lithium fluoride (LiF) is prepared, and then lithium ions and fluoride ions are economically recovered from lithium sludge and fluor

Abstract: The present disclosure relates to a method for recovery of valuable metals and a zeolite-containing material from a waste cathode material reaction vessel, in which valuable metals and a zeolite-containing material are recovered from a waste cathode material reaction vessel being discarded, and recycled as resources, thus reducing waste from the waste cathode material reaction vessel.

Abstract: The present disclosure relates to a co-polyester resin of a composition including dicarboxylic acid, wherein the composition includes C2-5 aliphatic diol and isosorbide in an amount of 70 mol to 97.5 mol and 2.5 mol to 30 mol, respectively, based on 100 mol of the dicarboxylic acid, and the dicarboxylic acid includes C2-6 aliphatic dicarboxylic acid and cyclic aromatic dicarboxylic acid.

Abstract: The present invention relates to a method for producing a cell having a genetic defect corrected, and a cell therapy agent comprising the cell, and, more particularly, to a method for producing a cell and a cell therapy agent comprising the cell, which comprise a method for isolating a cell from an individual, producing a chemically derived progenitor cell by processing a compound, and then correcting a mutant gene ex vivo. The cell therapy agent of the present invention has significantly less side effects such as an off-target effect and tumor generation, and has shown a Tyrosinemia type I treatment effect that is more significant than when a simple cell is transplanted, and thus, the cell therapy agent is expected to be widely usable in treatment fields for diseases caused by gene mutation, including Tyrosinemia type I.

Abstract: The present disclosure relates to a copolyester including a polymer formed by polymerization of monomers represented by the following Structural Formula 1 to Structural Formula 4: (in the above Structural Formula 1 to Structural Formula 4, R1 to R18 are identical to or different from each other and are each independently selected from the group consisting of H, substituted or unsubstituted linear or branched C1-C20 alkyl and substituted or unsubstituted C6-C20 aryl).

Abstract: The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitrile are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagnosing prostate cancer, containing the derivative as an active ingredient. A derivative according to the present invention has high binding capacity for PSMA, which is expressed in prostate cancer, by acting as a multi-ligand through the binding of three or six derivatives to one atom of technetium or rhenium, has excellent stability in human serum when administered in vivo, and is excreted into the kidney rather than the hepatobiliary tract because of high water solubility so that a clear image of a prostate cancer tumor site can be obtained, and thus the present invention can be effectively usable as a pharmaceutical composition for treating or diagnosing prostate cancer.

Abstract: The presented invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the presented invention binds to transcription factor CP2c to inhibit the formation of transcription factor CP2c complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer), thereby inducing cancer cell-specific cell death. A fatty acid is bound to the peptide to ensure stability enabling long-term sustenance in vivo.

Abstract: A carrageenan derivative according to the present disclosure can quickly and easily detect and label the presence of inflammation-related macrophages and, particularly, can accurately and easily identify M1-type macrophages highly associated with early inflammation. In addition, the carrageenan derivative has advantages in that it can be produced easily, environmental pollution is minimized because a small amount of organic solvent is used, and initial cost is low.

Abstract: Provided is a T1 contrast agent for magnetic resonance imaging. The T1 contrast agent includes fine iron oxide nanoparticle cores and micelles encapsulating the core particles. The micelles include a nonionic surfactant consisting of a hydrophilic moiety containing at least two chains and a hydrophobic moiety containing at least one C10-C30 hydrocarbon chain. The T1 contrast agent of the present invention is a novel one based on fine iron oxide nanoparticles that can replace conventional gadolinium-based T1 contrast agents. The T1 contrast agent based on fine iron oxide nanoparticles according to the present invention is harmless to humans, is rapidly distributed in the blood, and has a uniform size, ensuring its uniform contrast effect. In addition, the T1 contrast agent of the present invention enables image observation for at least 1 hour to up to 2 hours and is excreted through the kidneys and liver.

Abstract: The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer.

Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.

Abstract: The present disclosure relates to a copolyester including a polymer formed by polymerization of monomers represented by the following Structural Formula 1 to Structural Formula 4: (in the above Structural Formula 1 to Structural Formula 4, R1 to R18 are identical to or different from each other and are each independently selected from the group consisting of H, substituted or unsubstituted linear or branched C1-C20 alkyl and substituted or unsubstituted C6-C20 aryl).

Abstract: The present invention relates to a pigment-coupled mannosyl serum albumin complex and a lymph node-probing composition comprising the same. More particularly, when administered to mice, a pigment-coupled mannosyl serum albumin complex can be observed with the naked eye to exist in a condense state for a long period of time in the inguinal lymph node. Thus, the complex and a composition comprising the same can be useful for probing lymph nodes.

Abstract: The present invention relates to a complex prepared by conjugating indocyanine green to mannosyl serum albumin in order to overcome shortcomings such as low light stability and low in vivo stability of indocyanine green that is a fluorescent dye reagent that is used during surgical operations, a preparation method thereof, an optical imaging probe comprising the same, and a kit comprising the probe.

Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.

Abstract: A method for labeling exosomes with a radioactive substance using an amine group on surfaces of the exosomes includes providing a cell-derived exosome, treating a surface of the exosome with N-hydroxysuccinimide-azadibenzocyclooctyne (NHS-ADIBO), and mixing the treated exosome with N3-introduced chelator-radioactive substance to conduct a reaction between the chelator and an amine group present on the surface of the exosome, wherein the radioactive substance is introduced inside the exosome by the above reaction. The exosomes can be stably labeled at high labeling efficiency, and the exosomes can be favorably used as an agent for nuclear medicine imaging and therapeutic imaging for confirming the biological distribution of exosomes and whether the exosomes move to target organs and target diseases in animals including a human being.

Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.